Protara Therapeutics Stock (NASDAQ:TARA)


RevenueOwnershipFinancialsChart

Previous Close

$5.53

52W Range

$1.59 - $10.48

50D Avg

$2.93

200D Avg

$2.72

Market Cap

$192.88M

Avg Vol (3M)

$2.20M

Beta

1.79

Div Yield

-

TARA Company Profile


Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

26

IPO Date

Oct 22, 2014

Website

TARA Performance


TARA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-43.61M$-67.06M$-47.49M
Net Income$-40.42M$-64.81M$-47.13M
EBITDA$-43.61M$-8.03M$-47.25M
Basic EPS$-3.57$-5.76$-4.20
Diluted EPS$-3.57$-5.76$-4.20

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
SRRKScholar Rock Holding Corporation
MNPRMonopar Therapeutics Inc.
IKNAIkena Oncology, Inc.
SRZNSurrozen, Inc.
VCNXVaccinex, Inc.
XLOXilio Therapeutics, Inc.
TRVITrevi Therapeutics, Inc.
LYRALyra Therapeutics, Inc.